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Abstract 
Background: Vivax malaria is the predominant form of malaria outside Africa, affecting about 14 million people 
worldwide, with about 2.5 billion people exposed. Development of a Plasmodium vivax vaccine is a priority, and mero-
zoite surface protein 7 (MSP-7) has been proposed as a plausible candidate. The P. vivax genome contains 12 MSP-7 
genes, which contribute to erythrocyte invasion during blood-stage infection. Previous analysis of MSP-7 sequence 
diversity suggested that not all paralogs are functionally equivalent. To explore MSP-7 functional diversity, and to iden-
tify the best vaccine candidate within the family, MSP-7 expression and antigenicity during bloodstream infections 
were examined directly from clinical isolates.
Methods: Merozoite surface protein 7 gene expression was profiled using RNA-seq data from blood samples isolated 
from ten human patients with vivax malaria. Differential expression analysis and co-expression cluster analysis were 
used to relate PvMSP-7 expression to genetic markers of life cycle stage. Plasma from vivax malaria patients was also 
assayed using a custom peptide microarray to measure antibody responses against the coding regions of 12 MSP-7 
paralogs.
Results: Ten patients presented diverse transcriptional profiles that comprised four patient groups. Two MSP-7 
paralogs, 7A and 7F, were expressed abundantly in all patients, while other MSP-7 genes were uniformly rare (e.g. 7J). 
MSP-7H and 7I were significantly more abundant in patient group 4 only, (two patients having experienced longer 
patency), and were co-expressed with a schizont-stage marker, while negatively associated with liver-stage and 
gametocyte-stage markers. Screening infections with a PvMSP-7 peptide array identified 13 linear B-cell epitopes in 
five MSP-7 paralogs that were recognized by plasma from all patients.
Conclusions: These results show that MSP-7 family members vary in expression profile during blood infections; MSP-
7A and 7F are expressed throughout the intraerythrocytic development cycle, while expression of other paralogs is 
focused on the schizont. This may reflect developmental regulation, and potentially functional differentiation, within 
the gene family. The frequency of B-cell epitopes among paralogs also varies, with MSP-7A and 7L consistently the 
most immunogenic. Thus, MSP-7 paralogs cannot be assumed to have equal potential as vaccines. This analysis of 
clinical infections indicates that the most abundant and immunogenic paralog is MSP-7A.
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Background
Plasmodium vivax is a human malaria parasite of global 
importance, predominantly confined to populations out-
side sub-Saharan Africa [1]. The biology of P. vivax differs 
to that of Plasmodium falciparum; although P. vivax can 
cause severe and fatal disease, most infections are mild 
or asymptomatic. Unlike P. falciparum, P. vivax can form 
a dormant liver stage, the hypnozoite, and relapse due 
to parasite re-emergence is thought to have a major role 
in the epidemiology of vivax malaria [2]. In Asia, almost 
half of malaria infections are caused by P. vivax [3] and 
its importance continues to increase with the emergence 
of chloroquine and sulfadoxine–pyrimethamine resistant 
strains [4]. Therefore, the burden of vivax malaria outside 
Africa must not be under-appreciated and new control 
strategies, including a vaccine, are needed to prevent dis-
ease. While many vaccine candidates have been identi-
fied, few have progressed beyond pre-clinical evaluation. 
Circumsporozoite protein (CSP), ookinete surface pro-
tein Pvs25 and Duffy binding protein (PvDBP_RII) each 
elicit strong antibody responses that inhibit infection but 
have not yet produced sterile protection [5–9]. Detailed 
studies are needed of these and other antigens expressed 
in the bloodstream, which could provide vaccines that 
block transmission, either to the human host or the vec-
tor [10].
Merozoite surface protein 7 (MSP-7) is a multigene 
family conserved across Plasmodium but varying in copy 
number among species. In P. vivax, MSP-7 consists of 
12 paralogs (PvMSP7-A to -L), arranged in tandem at a 
single position on chromosome 12 [11–13]. All MSP-7 
proteins are developmentally regulated and expressed on 
the merozoite surface during asexual blood stages [14]. 
MSP-7 forms a multi-protein complex with merozoite 
surface protein 1 (MSP-1) on red blood cell band 3 that 
facilitates initial invasion [15–17]. Knock-out of Plasmo-
dium berghei MSP-7 in mouse reduces parasite propa-
gation [18], while disruption of P. falciparum MSP-7 
inhibits merozoite invasion [19]. Thus, MSP-7 collec-
tively is thought to have a key role in host cell invasion, 
but it is unclear if all paralogs have equivalent roles in 
this general phenotype. Recent population genetic analy-
sis has revealed consistent heterogeneity in allelic diver-
sity among the 12 genes, with PvMSP-7B, C, E, G, H, and 
I displaying much higher genetic diversity compared to 
A and F [20–22], which suggests that the gene paralogs 
have evolved under different functional constraints.
Merozoite surface protein 7 is a plausible vaccine target 
due to its putative role in erythrocyte invasion [23, 24]. 
Given that the scale of functional differentiation among 
paralogs is unknown, it is important to consider varia-
tion in expression profile, molecular interactions, and 
immunogenicity within the gene family in order to make 
informed decisions about choice of vaccine candidates. 
There is some understanding of MSP-7 expression pro-
files from global transcriptomes of synchronized P. vivax 
batch cell cultures measured using microarray [25] and 
RNA sequencing [26]. These suggested that PvMSP-7 
paralogs may display substantial variation in expres-
sion through the 48-h intraerythrocytic developmental 
cycle (IDC). In this study, variation in expression profiles 
among PvMSP-7 paralogs is examined using RNA-seq 
applied to asynchronous parasite populations isolated 
from ten clinical infections. Clustering analysis is used 
to associate PvMSP-7 paralogs with other developmen-
tally-regulated genes to better understand functional 
differentiation within the family. Clustering genes based 
on their transcriptional profiles can provide functional 
information for uncharacterized genes through their 
associations [27]. This approach revealed a novel func-
tion in osmotic protection during merozoite and ring 
stage for Cytochrome C heme-lyase in P. falciparum [28], 
and also determined that a conserved Plasmodium pro-
tein, PF3D7_0418300, clustered robustly with MSP-9 and 
two AP2 domain transcription factors (SPE2-interacting 
protein and APIAP2), indicating that it has a role in tran-
scriptional regulation [29].
The antibody responses of clinical isolates to a cus-
tom peptide microarray of all PvMSP-7 sequences are 
also examined to identify variation in immunogenicity 
among paralogs. Peptide microarrays have been used to 
characterize the immunogenicity of other malaria vac-
cine candidates. Nixon et  al. [30] identified five immu-
noreactive epitopes in P. falciparum schizont egress 
antigen 1 (PfSEA-1A) using a 15-mer peptide microar-
ray exposed to plasma from malaria patients in Kenya 
and showed these that antibody responses against these 
epitopes could produce a significant reduction of para-
sitaemia in vaccinated animals. Similarly, Quintana et al. 
[31] screened serum from infected children with a pep-
tide microarray containing three P. falciparum gene fami-
lies (PfEMP1, RIFIN, and SURFIN) implicated in severe 
malaria, and identified multiple reactive peptides. In P. 
vivax, Chootong et al. [32] used a microarray containing 
178 peptides of the entire Duffy binding protein (PvDBP) 
to identify ten linear B-cell epitopes; these were located 
mostly in the central protein domain, consistent with 
previous observations that this is essential for receptor 
recognition [33]. Thus, mapping epitopes is a key stage 
in identifying vaccine candidates, and, by extension, 
where multi-copy gene families are concerned, evaluating 
epitopic variation among paralogs is also important.
This study advances the understanding of functional 
variation within the MSP-7 gene family, a vital compo-
nent of the parasite cell surface during the asexual blood 
stages of P. vivax and other species. It shows that paralogs 
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vary substantially in their abundance during the IDC and 
in their immunogenicity during clinical infections, and, 
consequently, it cannot be assumed that all MSP-7 pro-
teins will make equally suitable antigens for experimental 
vaccines.
Methods
Human ethics statement
This work was approved by the Institutional Review 
Board for Human Research of the Faculty of Medicine, 
Chulalongkorn University, Thailand (IRB No. 104/59). 
Written consent was obtained from all participants or 
from their parents or guardians prior to admission into 
the study.
Sample collection and processing
For transcriptomic analysis, five human patients were 
recruited from each of two malaria endemic areas of 
Thailand: (i) Ubon Ratchathani, located along the North-
eastern border between Thailand and Cambodia, and (ii) 
Yala, located along the Southern border between Thai-
land and Malaysia. Patients of any age who attended 
malaria clinic with fever but did not show severe malaria 
symptoms were recruited to the study. Hence, all patients 
were symptomatic and were asked to provide informa-
tion on the days of fever they had experienced (Table 1). 
Patients were screened with microscopic examination 
by an experienced laboratory technician and ~ 600  μL 
of venous blood were collected from P. vivax-infected 
patients. Blood samples were preserved in  RNAlater® 
solution (Ambion, Grand Island, NY, USA) with a 1:1 
ratio and stored at − 20 °C until processing. Whole RNA 
was extracted from 500 μL of each blood sample using a 
QIAamp RNA blood mini kit (Qiagen, Hilden, Germany), 
following the manufacturer’s recommendations and 
stored at − 80 °C until used. A nested rRNA polymerase 
chain reaction (PCR) capable of detecting all five human 
malaria species [34] was used to confirm the presence of 
P. vivax and the absence of other species.
For screening of the MSP-7 peptide microarray, 
plasma was collected from 64 vivax-malaria patients 
from Ubon Ratchathani province (North-eastern Thai-
land) between 2013 and 2016. Negative controls, i.e. 
malaria naïve donors (n = 20), were recruited from 
non-malaria endemic areas at Chulalongkorn hospi-
tal, Bangkok. These patients had not lived/spent time 
in malaria-endemic regions of Thailand, as far as was 
known. Approximately 2  mL of venous blood was col-
lected into EDTA anticoagulant from patients with sin-
gle-strain P. vivax infection, confirmed by nested rRNA 
PCR [34], and plasma was collected by centrifugation. 
These plasma were sorted into five experimental age 
cohorts: 0–14 years (n = 11), 15–29 years (n = 22), 30–44 
(n = 19), 45–59 (n = 10) and 60–74 (n = 2). A master 
plasma sample was prepared for each age group by pool-
ing 5 µL of plasma from each vivax-infected patient. All 
samples were preserved at − 80 °C until use.
RNA sequencing
Ten RNA samples were treated with DNase, followed 
by Epicentre Globin-Zero Gold kit to deplete rRNA and 
globin transcripts. RNA-seq libraries were prepared at 
the Centre for Genomic Research, University of Liv-
erpool using the NEBNext Ultra Directional protocol. 
The RNA-seq libraries were sequenced on the Illumina 
HiSeq4000 platform in a single lane, generating ~ 30 
million paired-end 150  bp reads for each sample. The 
quality of the libraries was affirmed by Agilent 2100 
Table 1 Ten patients diagnosed with P. vivax infection were recruited in the study from two malaria clinics in Thailand: 
Ubon Ratchathani and Yala
Patients ranged between 14 and 50 years of age. Information regarding days of patency was provided by patients to medical officers during their visit
NR not recorded
Sample Age (years) Gender Province Days of patency Parasitaemia (parasites/200 
leukocytes)
Patient 
group
UBT3086 50 Male Ubon Ratchathani 2 220 1
UBT3087 NR NR Ubon Ratchathani 3 152 2
UBT3089 41 Male Ubon Ratchathani 2 60 2
UBT3090 14 Male Ubon Ratchathani 2 226 2
UBT3091 37 Male Ubon Ratchathani 3 383 1
YL3111 26 Female Yala 2 360 3
YL3112 45 Male Yala 2 20 3
YL3113 15 Male Yala 7 160 4
YL3114 30 Female Yala 2 40 3
YL3115 46 Female Yala 7 360 4
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Bioanalyser. RNA-seq data have been deposited in the 
EMBL-EBI ArrayExpress database (http://www.ebi.ac.uk/
array expre ss/exper iment s) under Accession Number 
E-MTAB-6753.
Estimation of transcript abundance
The initial processing and quality assessment of the raw 
reads began with base calling and de-multiplexing of 
indexed reads using CASAVA version 1.8.2 (Illumina) 
to produce ten samples from one lane of sequence data 
in fastq format. The Illumina adapter sequences were 
trimmed from the raw fastq files by using Cutadapt ver-
sion 1.2.1 [35]. The option “-O 3” was specified to trim 
off the 3′ end of any reads that matched to the adapter 
sequence over at least 3  bp. The reads were further 
trimmed to remove low quality bases, using Sickle version 
1.2 with a minimum window quality score of 20. Before 
mapping the filtered reads to the reference genome, 
reads shorter than 10  bp were removed. Subsequently, 
all the filtered reads were mapped to the human genome 
(GRCH37) using TopHat2 [36]. The unmapped reads 
were then aligned to the PvP01 reference genome [37] 
using TopHat2. Following the alignment of reads to the 
P. vivax genome, the read counts of each gene were quan-
tified with featureCounts [38]. Read counts were esti-
mated by dividing the total number of mapped reads by 
the length of the gene, and then scaling the estimates to 
one million. The genome-wide coverage of each sample 
was determined using Qualimap 2 [39]. Transcript abun-
dance, expressed as Read Count per Million bases (CPM) 
was estimated by DESeq2 [40]; this program normal-
izes data for both library size and compositional differ-
ences (e.g. the presence and absence of large abundance 
transcripts) using median ratios of  log2-transformed 
raw counts. To establish reproducibility among the tran-
scriptomes and to identify possible low-quality outliers, 
Pearson correlations of transcript abundances (N = 5838) 
were estimated for each pair of samples in R version 3.4.3 
and corrplot [41].
Differential gene expression analysis
Principal component analysis (PCA) was performed on 
the log-transformed, normalized CPM values for 5838 
genes estimated by DESeq2 for ten patients. The PCA 
consistently placed the ten samples into four groups, 
which were adopted subsequently to identify differen-
tially expressed genes (DEGs) in a pairwise manner, 
using DESeq2 [40]. Genes with a false discovery rate 
(FDR) threshold below 0.05 after correcting for multiple 
tests were deemed significantly differentially expressed. 
Additionally, differential expression analysis was also 
performed analysis with EdgeR [42], but the DEGs and 
PCA plot did not deviate substantially from the DESeq2 
results. Thus, the latter was used in downstream analyses.
Co‑expression analysis
The DEGs identified for each patient group were 
imported into coseq, an R package to identify clusters of 
co-expressed genes [43]. The purpose was to associate 
differentially-expressed PvMSP-7 genes with other genes 
that are known to be developmentally regulated. A robust 
association with a known life-stage marker would then 
allow developmental regulation within the PvMSP-7 fam-
ily to be inferred. Coseq uses Gaussian mixture models to 
cluster all the genes based on the proportion of normal-
ized counts in their expression profiles. The DESeq2 data 
were fitted to a Gaussian mixture model on either arcsine- 
or logit-transformed normalized profiles. One hundred 
clusters were tested in each transformation with the fol-
lowing commands; arcsin_transformed < − coseq(counts, 
K = 2:100, model = “Normal”, transformation = “arcsin”) 
and logit_transformed < − coseq(counts, K = 2:100, 
model = “Normal”, transformation = “logit”). To choose 
accurately between two transformation models, coseq 
calculated the corrected integrated completed likelihood 
(ICL) values from these two models and selected the 
number of clusters and preferred model-transformation 
based on the highest corrected ICL value.
Enrichment analysis and pathway identification
To infer the functional consequences of differential gene 
expression between patient groups, enrichment analysis 
was carried out on functional terms associated with the 
DEGs, using PlasmoDB release 35 [44]. First, heat-maps 
were plotted for the DEGs from each patient group com-
parison, relating Euclidian distance-based dendrograms 
of all DEG expression profiles and each patient group. 
These heat-maps neatly divided DEGs into clades based 
on their expression profiles and these were then sub-
jected to enrichment analysis for both Gene Ontology 
(GO) terms [45] and Kyoto Encyclopaedia of Genes and 
Genomes (KEGG) pathways [46]. Functional terms and 
pathways were deemed significant where the adjusted 
p-value was < 0.05. Second, the genes belonging to clus-
ters returned by Coseq were also subjected to the same 
enrichment analyses.
Microarray screening
A custom peptide microarray was designed that 
included the entire, predicted amino acid sequences 
of all 13 PvMSP-7 paralogs. The microarray contained 
15-mer peptides of each PvMSP-7 gene with an overlap 
of 11 amino acids, printed in duplicate: a total of 2346 
peptides. The slides were manufactured by PepperPrint 
(Heidelberg, Germany) and coated with a poly(ethylene 
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glycol)-based graft copolymer with a thickness of 
13.5  nm and an additional three amino acid linker 
(β-alanine, aspartic acid, and β-alanine), which ensure 
optimal epitope orthogonal attachment and presenta-
tion. Each microarray slide consisted of three identical 
array copies, each framed by flag anti-HA (YPYCVP-
DYAG, 52 spots) as a quality control measurement. The 
signal intensities of these control peptides indicate the 
spot uniformity and binding specificities.
Each microarray was treated with 1% bovine serum 
albumin (BSA) blocking buffer for 30 min at room tem-
perature. To determine the background intensity, one 
microarray was then incubated with goat anti-human 
IgG (H + L) DyLight680 antibody (Rockland Immuno-
chemical Inc., USA) that was diluted 1:2500 in stain-
ing buffer (phosphate-buffered saline (PBS) with 0.05% 
Tween20 and 10% blocking buffer). Clean microar-
rays were then incubated overnight at 4  °C with 10 µL 
pooled plasma from one of five patient age cohorts 
(see above), diluted 1:50 with staining buffer. The pep-
tide microarray was washed three times with stand-
ard buffer (PBS with 0.05% Tween20, pH 7.4) using 
an orbital shaker at 140  rpm. The microarrays were 
washed in 1 mM Tris dipping buffer (pH 7.4) to remove 
all contaminants from the array surface and dried by 
tapping the edge of the slide on tissue paper. To ensure 
that all microarrays were responding correctly, all steps 
were repeated with the Cy3-conjugated anti-HA con-
trol antibody supplied by PepperPrint (Heidelberg, 
Germany). A sixth microarray was assayed to provide 
a negative control consisting of naïve human plasma 
taken from individuals in malaria-free areas.
Microarrays were illuminated on an Agilent 
G2565CA microarray scanner, with the AgilentHD red 
colour single channel at 10  µm resolution and output 
to a 16-bit greyscale tiff files. The mean and median of 
local background and foreground fluorescence inten-
sity values for all peptide spots were quantified using 
PepSlide analyser (SICASYS Software, Heidelberg, 
Germany). Correction for background intensity and 
normalization for variation between and within arrays 
were performed using the LIMMA package [47] imple-
mented in R version 3.4.3. Background correction was 
performed on each array by subtraction of local back-
ground estimates from each foreground intensity value 
[48]. This step was performed to eliminate the effects 
of non-specific binding across the arrays. Spot intensi-
ties were also normalization for between-array varia-
tion using the quantile principle in LIMMA [49]. The 
quantile function compensates for systematic measure-
ment errors between-arrays, producing a more uniform 
intensity distribution and leaving only the true biologi-
cal differences in the datasets.
Microarray statistical analysis
Statistical analysis was performed using the LIMMA 
package [47]. Normalized data were fitted to a linear 
model and peptides with significant responses to anti-
body, i.e. normalized fluorescent intensity significantly 
greater than background levels, were determined in all 
experimental groups by comparing the log transforma-
tion of expression intensity. A simple Bayesian model was 
used to estimate significant peptides between the experi-
mental group and negative control [47, 49]. The sum-
mary statistics were computed by the eBayes() function, 
returning a list of significantly expressed peptides were 
displayed. Benjamini and Hochberg’s method or false 
discovery rate (FDR) was used to correct the p-value for 
multiple tests. FDR < 0.05 were considered statistically 
significant.
Results
Data summary
RNA sequencing generated ~ 30 million 150  bp paired-
end reads for each of ten clinical isolates (Table 2). The 
samples were collected from field hospitals in remote 
areas and suffered a variable degree of degradation 
prior to sequencing; RIN values were consistent but low 
(between 2 and 2.8); moreover, sequence coverage was 
variable and relatively low for some isolates. For each 
isolate, all reads were aligned to the human genome 
(GRCh37) and then the unmapped reads were aligned 
to the P. vivax reference genome (PvP01; [37]). Typi-
cally, more than 70% of reads were derived from human, 
while reads mapping to P. vivax ranged between 0.78 and 
22.38%. Mean genome coverage varied widely among the 
ten isolates, between 1.07× and 78.52× (mean = 18.8×). 
Isolate UBT3089 has the highest mean coverage of 
78.52×, while five samples have a value < 10×. Global 
transcript abundance, expressed in Read Count per Mil-
lion bases (CPM) and normalized for gene length and 
read number, was calculated for all genes using DESeq2 
after mapping the data to the reference genome with 
TopHat2 (Additional file 1). To evaluate the reproducibil-
ity of the results in the light of this variation in coverage, 
Pearson correlation coefficients were calculated between 
each sample for gene-level CPM estimates; such coeffi-
cients ranged from 0.59 to 0.91 (mean = 0.72).
Principal component analysis
Plasmodium vivax infrapopulations in clinical settings 
usually comprise variable mixtures of different para-
site life stages, which, depending on the precise com-
positional balance, could be reflected in stage-specific 
expression patterns. Unfortunately, the proportions of 
parasite developmental stages could not be determined 
from microscopic slides as these were not retained by 
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the field hospitals. Instead, the relative proportions of 
parasite stages were characterized by quantifying the 
expression of stage-specific markers. Ten patients were 
separated into groups based on a principal component 
analysis of genome-wide transcript abundance, which 
was independent of age and days of patent infection (i.e. 
fever). The ten patients clustered into four groups using 
the expression profiles of 5838 genes produced by the 
DESeq2 analysis (Fig. 1; Additional file 1). Together, the 
two largest principal components account for 69% of the 
total variation in transcript abundance. These groups 
do not reflect coverage, so YL3113 can be clearly dis-
tinguished from YL3111, YL3112 and YL3114, despite 
these four samples having a comparable low coverage; 
similarly, UBT3089 and UBT3091, which had the high-
est sequence coverage values do not cluster together. This 
reassures that the variation seen is not simply an arte-
fact of the degree of degradation within the samples. The 
study focused on patient group 4 because these patients 
had a distinct MSP-7 expression profile (see below). 
Patient group 4 included two patients that had experi-
enced longer patency (i.e. 7 days), than patients in groups 
1–3, who had experienced fever for 2–3 days. These four 
patient groups were the basis for pairwise comparison 
of PvMSP-7 expression and analysis of differential gene 
expression. The relatedness among the ten parasite iso-
lates was assessed to rule out the possibility that relat-
edness might explain the patient groups. 42,988 biallelic 
single nucleotide polymorphisms (SNPs) were extracted 
from mapping data for each RNA-seq dataset. Principal 
component analysis of these SNPs shows that isolates 
cluster by geographical origin, and do not recapitulate 
the patient groups (Additional file 2). Therefore, affinities 
among isolates based on transcript abundance are not 
simply a reflection of genetic relatedness or geographical 
origin.
PvMSP‑7 expression profiles
To investigate the expression of PvMSP-7 during diverse 
clinical infections, and to examine variation in transcrip-
tional profile within the family, normalized transcript 
abundance in each isolate for the 12 paralogous genes 
was plotted as a heat map, shown in Fig. 2. From the rela-
tionships among isolates, seen across the top of Fig. 2, it 
is immediately clear that there is substantial variation in 
PvMSP-7 expression among patients, which only partly 
coincides with patient groups, i.e. genome-wide expres-
sion profile. There are also consistent differences among 
PvMSP-7 paralogs; 7A and 7F display higher abundance 
than all others (mean log2 normalized read counts of 
7.76, 7.19, and 6.28, respectively). Even in patients with 
otherwise low PvMSP-7 expression, such as YL3112 and 
YL3114, these two paralogs maintain the same high level 
of expression. Conversely, 7E, 7G, and 7J were uniformly 
rare transcripts (mean log2 normalized read counts of 
1.44, 0.81 and 0.33, respectively); the latter is perhaps 
unsurprising since PvMSP-7J is a pseudogene [13]. Other 
paralogs are only transiently abundant, for example, 7H 
and 7I (mean log2 CPM of 4.03 and 3.58 respectively), 
were highly abundant in patient group 4 only (mean 
log2 CPM of 8.65 and 7.29 respectively); indeed, in these 
two patients that had experienced longer patency, their 
expression was comparable to 7A and 7F. Hence, when 
differential expression analysis was performed on nor-
malized transcript abundance values (data shown in 
Additional file 3), significant differences in the abundance 
Table 2 Summary statistics of RNA preparation, RNA sequencing, read mapping to the human GRCh37 and P. vivax P01 
genomes, and  sequence coverage, for  10 clinical isolates from  vivax malaria patients taken from  two regions: Ubon 
Ratchathani (UBT; North-East) and Yala (YL; South)
a After adapter and quality trimming
Isolate Total RNA (ng) RNA integrity 
number (RIN)
Total read 
 pairsa
Pair reads 
mapped 
to human
Percentage 
of reads 
mapped 
to human
Pair reads 
mapped to P. 
vivax
Percentage 
of reads 
mapped to P. 
vivax
Mean 
sequence 
coverage
1 UBT3086 585.2 2 29,157,609 22,771,884 78.10 346,899 1.20 1.82
2 UBT3087 392 2.4 36,549,438 29,392,764 80.42 977,753 2.68 17.67
3 UBT3089 1498 2.3 30,083,802 23,272,992 77.36 3,035,144 10.09 78.52
4 UBT3090 719.6 2.3 30,397,809 22,226,523 73.12 3,267,128 10.75 17.59
5 UBT3091 504 2.3 28,550,673 18,312,289 64.14 6,388,456 22.38 42.07
6 YL3111 627.2 2.3 29,500,938 26,039,174 88.27 580,181 1.97 3.18
7 YL3112 1005.2 2.3 32,578,915 27,732,216 85.12 913,421 2.80 4.95
8 YL3113 280 2 26,853,921 21,654,627 80.64 209,249 0.78 1.07
9 YL3114 1470 2.8 31,860,822 27,764,327 87.14 350,337 1.10 1.88
10 YL3115 641.2 2.5 32,987,343 24,102,143 73.05 3,469,628 10.52 20.13
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of PvMSP-7H were found (mean log2FC = 4.86; mean 
 padj = 0.026) when patient group 4 was compared with 
all other groups; and likewise for 7I (mean log2FC = 3.84; 
mean  padj = 0.024) when patient group 4 was com-
pared with groups 2 and 3, and 7C (log2FC = 6.48; 
 padj = 0.0002), when compared with patient groups 1 
and 3. Finally, MSP-7L (log2FC = 3.64;  padj = 0.007), 7K 
(log2FC = 4.54;  padj = 0.03) were differentially expressed 
when patient group 4 was compared with group 3 only. 
In contrast, no significant differences in PvMSP-7 expres-
sion were found in pairwise comparisons among patient 
groups 1–3.
Differential gene expression analysis
Given that critical differences were seen in expression 
profile among PvMSP-7 paralogs in distinct patient 
groups, it was necessary to better understand the global 
gene expression landscape in these groups, to help 
explain the PvMSP-7 patterns. Having identified differen-
tially expressed genes (DEGs) in pairwise comparisons of 
patient groups using DESeq2, the log2 normalized read 
counts for all DEGs in each comparison were plotted in 
heat-maps. The highest number of DEGs (1493; Addi-
tional file 3) was observed between patient groups 3 and 
4, and these are plotted in Fig.  3. The heat-map relates 
gene expression profiles (rows) with clinical isolates (col-
umns); the vertical dendrogram clusters genes based 
on their expression profile, the horizontal dendrogram 
clusters isolates based on their global expression pro-
file. The heat-map is divided into sectors based on clades 
observed in vertical dendrogram, and Gene Ontology 
enrichment analysis was performed on each sector.
The 1493 DEGs identified between patient groups 3 
and 4 may be segregated into five sectors (i to v). Genes 
in sector i (n = 252) and ii (n = 456) were significantly less 
abundant in group 4 and enrichment analysis showed 
that these genes are associated with Nucleic acid bind-
ing, ATP-dependent peptidase activity, helicase activity, 
tRNA processing, nitrogen compound metabolism, and 
RNA metabolism. Genes in sector iv (n = 192) were also 
more abundant in group 3 and GO terms associated with 
these related to macromolecular complex, eukaryotic 
UBT3091
UBT3086
UBT3090
UBT3089
UBT3087
YL3111
YL3112
YL3114
YL3113
YL3115
Group 1
Group 2
Group 3
Group 4
Fig. 1 Principal component analysis (PCA) of genome-wide expression profiles for ten clinical isolates (5838 genes). The principal components 
were calculated from normalized read counts implemented in DESeq2. Axes represents the first and second principal components (PC1 and PC2), 
accounting for 42% and 27% of total variance, respectively. Each dot represents an individual isolate, and isolates were divided into four ‘patient 
groups’ based on the PCA
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translation initiation factor 3 complex, Chaperonin-con-
taining T-complex, small molecule metabolic process, and 
protein folding. Conversely, genes in sector iii (n = 403) 
and iv (n = 190) were significantly more abundant in 
group 4 isolates. These genes were enriched for GO 
terms associated with Rhoptry, cell surface, protein–DNA 
complex, nucleus, regulation of metabolic process, DNA 
binding, and protein binding. PvMSP-7K, 7I, 7H, 7C, and 
7L were included among the sector iii genes.
Comparisons of patient group 4 with 1 and 2 identified 
fewer DEGs but consistent patterns of differential expres-
sion. A heat-map of the 251 DEGs detected between 
Groups 4 and 1 is shown in Additional file  4. Sector i 
contains genes that are significantly less abundant in 
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1
Fig. 2 Expression profiles for 12 PvMSP-7 paralogs in ten clinical isolates. The heat-map describes log2-transformed normalized read counts from 
the DESeq2 analysis; shading reflects transcript abundance from low (red) to high (black) shading. Clustering in the y-axis dendrogram reflects 
similarity in profile between genes. Clustering in the x-axis dendrogram indicates the similarity of PvMSP-7 expression profile between patients; for 
instance, patient group 4 isolates display a very similar profile for PvMSP-7
(See figure on next page.)
Fig. 3 Expression profiles of differentially expressed genes (DEGs) in a comparison of patient groups 3 and 4 (n = 1493). The heat-map shows 
expression profile across five clinical isolates, generated from log2-transformed normalized read counts. Clustering in the y-axis dendrogram reflects 
similarity in profile between DEGs. Clustering in the x-axis dendrogram indicates the similarity of differential expression between patients. The 
heat-map is divided into five sectors based on y-axis clustering. For each sector, the results of enrichment analysis of Gene Ontology (GO) terms are 
shown on the right. GO terms with significant enrichment within a given heat-map sector are listed with their description, ontological category [i.e. 
biological process (BP), molecular function (MF), cellular compartment (CC)], frequency in the background gene set (‘size’) and incidence within the 
heat-map sector (‘count’). Significance threshold was p-value < 0.05 after Bonferroni correction
Page 9 of 20Cheng et al. Malar J          (2019) 18:197 
0 4 8 12
Log2 (normalised read count)
Group
3
4
YL
31
13
YL
31
15
YL
31
14
YL
31
12
YL
31
11
Term/
Description
GO:0003723 (MF)
RNA binding
GO:0003676 (MF)
Nucleic acid binding 
GO:0004176 (MF)
ATP-dependent peptidase activity
GO:0004386 (MF)
Helicase activity  
Size
191
507
2
38
Count
22
44
2
7
Adjusted
p-value
0.0168
0.0168
0.0291
0.0337
Term/
Description
GO:0008033 (BP)
tRNA processing
GO:0006807 (BP)
Nitrogen compound metabolic 
process
GO:0016070 (BP)
RNA metabolic process
Size
29
495
266
Count
9
57
35
Adjusted
p-value
0.0292
0.0386
0.0434
Term/
Description
GO:0020008 (CC)
Rhoptry 
GO:0009986 (CC)
Cell surface
Size
24
46
Count
12
10
Adjusted
p-value
7.46E-06
0.0448
Term/
Description
GO:0032991 (CC)
Macromolecular complex
GO:0005852 (CC)
Eukaryotic translation initiation
factor 3 complex
GO:0005832 (CC)
Chaperonin-containing T-complex
Size
520
10
8
Count
51
5
3
Adjusted
p-value
5.79E-05
0.0001
0.0272
GO:0044712 (BP)
Single-organism catabolic process
GO:0044281
Small molecule metabolic process
GO:0006457 (BP)
Protein folding
44
183
55
10
22
10
0.0015
0.0040
0.0006
Term/
Description
GO:0032993 (CC)
Protein-DNA complex
GO:0005634 (CC)
Nucleus
Size
15
235
Count
5
19
Adjusted
p-value
0.0031
0.0121
GO:0003677 (MF)
DNA binding
GO:0005515 (MF)
Protein binding 
163
491
17
33
0.0059
0.0111
GO:0019222 (BP)
Regulation of metabolic process
98 11 0.0458
i
ii
iii
iv
v
Page 10 of 20Cheng et al. Malar J          (2019) 18:197 
group 4 (n = 125); these are associated with GO terms for 
Cell surface, Maurer’s cleft, host cell surface binding, and 
Uridylyltransferase activity, and implicate such genes as 
reticulocyte binding surface protein (PvP01_00004240; 
 log2 FC = 9.27,  padj = 2.97e−15), tryptophan-rich pro-
tein (PvP01_0504200;  log2 FC = 7.32,  padj = 0.001) and a 
small heat shock protein HSP20 (PvP01_0518800;  log2 
FC = 5.17,  padj = 0.034). Sector ii also contains genes that 
are expressed more in group 1 isolates (n = 71); here, 
GO terms are associated with crystalloid, cell surface, 
and host cell cytoplasm. Sector iii (n = 22) and sector iv 
(n = 33) contain genes that were more abundant in group 
4 isolates. GO terms enriched within this gene set con-
cern Rhoptry, cell surface, and proteolysis, and implicate 
known invasion-related genes such as high molecular 
weight rhoptry protein 3 (PvP01_0703800;  log2 FC = 6.38, 
 padj = 0.006), high molecular weight rhoptry protein 2 
(PvP01_0727900;  log2 FC = 5.81,  padj = 0.0004), 6-cysteine 
protein (PvP01_1136400;  log2 FC = 6.16,  padj = 0.008) and 
merozoite surface protein MSA180 (PvP01_0814200; 
 log2 FC = 7.25,  padj = 9.46e−5). The comparison of patient 
groups 2 and 4 is shown in Additional file 5. 351 DEGs 
were identified and these segregate into five sectors in the 
heat-map. No distinct expression patterns are observed 
within sector i (n = 99) and ii (n = 49). Genes in sector 
iii (n = 47) and iv (n = 142) were less abundant in group 
4 isolates. They are associated with functional terms for 
purine metabolism and host cell surface binding.
While the analysis of differential expression shows 
that these clinical isolates have different transcrip-
tional landscapes, and clearly associate expression of 
PvMSP-7C, 7H and 7I with patient group 4 only, rela-
tively few DEGs contribute to the enrichment analysis 
and so enriched functional terms have limited capac-
ity to explain the transcriptional differences. Among the 
DEGs, various specific markers of parasite development 
were observed, such as schizont egress antigen-1 (SEA1; 
PVP01_0607000), which was more abundant in patient 
group 4 than 3  (log2 FC = 4.92;  padj = 9e−06) and game-
tocyte development protein 1 (GDV1; PVP01_0734100), 
which was most abundant in patient group 3 than 4  (log2 
FC = 3.73;  padj = 0.0001). Thus, to explore developmental 
composition as an explanation of transcriptional differ-
ences, associations between PvMSP-7 expression profiles 
and such specific markers were sought using co-expres-
sion analysis.
Co‑expression analysis
Co-expression analysis using the coseq package was 
applied to integrate DEG transcript abundance in patient 
group 4 with each of the other groups. Co-expression 
analysis would typically be applied to a series of longitu-
dinal samples taken over a time-course, but here it was 
applied it to ten clinical isolates after ordering these by 
patient group. Given that patient group 4 has a signifi-
cantly different MSP-7 expression profile to other groups, 
the analysis examined whether these genes are co-
expressed in group 4 with developmental stage-specific 
markers. If so, associations between MSP-7 and develop-
mental markers would help to explain the essential differ-
ences between the patient groups.
The correlation of expression profiles for 1493 DEGs 
across patient groups 4 and 3 produced 14 transcript 
clusters (Additional file 6). Of these, five clusters (includ-
ing 740 DEGs) are of interest because they describe a 
dynamic that clearly distinguishes the patient groups; 
these are shown in Fig.  4. The top panel (Fig.  4a) 
describes a cluster that is more abundant in patient group 
4 than group 3. This cluster included PvMSP-7K, 7I, 
7H and 7C, reflecting the differential expression analy-
sis, in which  log2 fold change ranged from 4.21 to 6.48. 
These MSP-7 transcripts were co-expressed with several 
stage-specific genes with known functions in erythrocyte 
invasion, such as early-transcribed membrane protein 
(ETRAMP, PvP01_0618300), schizont egress antigen-1 
(SEA1, PvP01_0607000), rhoptry neck protein 4 (RON4, 
PvP01_0916600). Figure  4b describes a transcript clus-
ter that included MSP-7L  (log2 FC = 3.64) and other 
invasion-related genes, such as plasmepsin V (PMV, 
PvP01_1231100), merozoite organizing protein (MOP, 
Fig. 4 Co-expression analysis of genes differentially expressed between patient groups 3 and 4. Coseq was used to generate clusters of genes 
with positively correlated transcription profiles. 1493 DEGs formed 14 clusters; five clusters with dynamics that clearly distinguish the two patient 
groups are shown here. a, b Concern transcripts that are abundant in patient group 4 and positively correlated with PvMSP-7 expression. c–e 
Concern transcripts that were abundant in patient group 3, and were negatively correlated with PvMSP-7l. Boxplots (left) represent expression 
values for all genes in a cluster (Log2-transformed, normalized read counts) from an individual patient, shaded by patient group; the black line 
connecting boxplots is the mean expression value of all genes in the cluster. a PvMSP-7K, 7I, 7H and 7C (only 7H is shown) were co-expressed with 
91 other genes including various invasion-related genes such as ETRAMP, SEA1, and RON4. b A fifth MSP-7 gene, PvMSP-7L, was co-expressed with 
125 other genes including PMV, MOP, and RON5. c A gametocyte stage-specific marker, gamete antigen 27/25, was absent in patient group 4 but 
positively correlated with TRAG36 and PIR genes. d A cohort of 168 genes that are abundant in patient group 3 but absent in group 4. e Another 
stage-specific marker, liver stage antigen 3, is abundant in patient group 3 and co-expressed with 204 other genes. Pearson’s correlation coefficient 
(r) for abundance values of MSP-7H and selected genes are shown
(See figure on next page.)
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PvP01_0715400), and rhoptry neck protein 5 (RON5, 
PvP01_0517600).
Contrasting with these two clusters, Fig.  4c–e dis-
plays transcriptional profiles that are most abundant 
in patient group 3, declining in group 4. These clusters 
include other stage-specific markers indicative of dif-
ferent parasite life stages, such as gamete antigen 27/25 
(PvP01_0422700), sporozoite and liver stage tryptophan-
rich protein (TryThrA, PvP01_0532600), and liver spe-
cific protein 3 (PvP01_0405000). Besides these, various 
multi-copy gene families typical of asexual-stage cells are 
co-expressed, such as tryptophan-rich protein (TRAG36, 
PvP01_0119200), Plasmodium interspersed repeat (PIR, 
PvP01_0816000), Plasmodium exported protein (EXP, 
PvP01_0300700) and erythrocyte membrane-associated 
antigen (EMAA, PvP01_0103700). Pearson’s correla-
tion coefficient (r) was estimated for each stage-specific 
marker in relation to MSP-7H. Overall, positive cor-
relations (r > 0.90) were observed for schizont/merozo-
ite-stage expression gene while, negative correlations 
(r > − 0.85) were seen with sporozoite, liver, and game-
tocyte stage markers. MSP-7I and 7C genes enriched in 
patient group 4 gave consistent results when correlated 
with stage-specific genes.
The correlation of expression profiles for 251 DEGs 
across patient groups 4 and 1 produced seven transcript 
clusters (Additional file 6); four are shown (including 208 
DEGs) in Additional file 7. In this comparison, PvMSP-
7H and 7C were significantly differentially expressed  (log2 
FC = 5.31, 7C and 6.33, respectively). These two PvMSP-7 
paralogs were placed in different clusters (Additional 
file  7a and b), although weakly positively co-expressed 
(r > 0.60). They were significantly co-expressed with 
various invasion-related genes, including PIESP1, PMV, 
rhoptry neck protein 3 (RON3, PvP01_1469200), serine-
repeat antigen-1 (SERA, PvP01_0417100), subtilisin-like 
protease 3 (SUB3, PvP01_1026800), and high molecular 
weight rhoptry protein 3 (RhopH3, PvP01_0703800). 
Genes negatively associated with PvMSP-7H and 7C 
included two gametocyte stage-specific markers (gam-
ete release protein (PvP01_0115300) and gamete antigen 
27/25 (PVP01_0422700).
The correlation of expression profiles for 351 DEGs 
across patient groups 4 and 2 produced seven transcript 
clusters (Additional file  6); four clusters (comprising 
176 DEGs) are shown in Additional file  8. These clus-
ters present a similar picture to that above. Expression 
of MSP-7H and 7I was positively correlated with SEA1 
(Additional file  8b), but contrasted with expression of 
liver specific protein 3 (Additional file  8c), and gamete 
antigen 27/25 (Additional file 8d), as well as various Plas-
modium exported proteins and tryptophan-rich proteins 
associated with asexual stages.
From the differential expression and co-expression 
analyses, it is apparent that MSP-7H and 7I are posi-
tively co-expressed with the schizont stage-specific 
marker SEA1, and various other invasion-related genes. 
This indicates that isolates from patient group 4 are dis-
tinguished from other groups by a greater proportion of 
schizonts in the parasite infrapopulation, relative to other 
life stages. Accordingly, MSP-7H and 7I have a nega-
tive association with liver-stage and gametocyte-stage 
markers.
Peptide microarray assay of PvMSP‑7 linear B‑cell epitopes
Immuno-reactive linear B-cell epitopes were identi-
fied by screening plasma from naturally-infected indi-
viduals with a customized PvMSP-7 peptide microarray, 
which consisted of 1173 15-mer peptides spanning the 
complete coding sequence of 12 PvMSP-7 paralogs (see 
Additional file 9). The peptide microarray was incubated 
with plasma from patients with single P. vivax infection, 
pooled into five age groups. The purpose of separat-
ing plasma into these arbitrary age divisions was not to 
examine the effect of age per se, but to ensure that the 
epitopes identified were significantly more responsive 
than naïve samples regardless of patient age. A second-
ary goat anti-human IgG antibody with conjugated 
fluorophore (DyLight 680) was applied to determine 
the plasma reactivity profile for each peptide. Figure  5 
shows that plasma from the 30–44 age group displayed 
immuno-reactivity to the most epitopes (Fig.  5c), while 
the fewest responses was observed from the 45–59 age-
group (Fig.  5d). A negative control comprised plasma 
from malaria-naïve individuals; some fluorescence was 
observed from the negative control, but these responses 
were relatively weak. Furthermore, responses from the 
naïve control did not generally coincide with immune-
reactive peptides bound by plasma samples. By compar-
ing the spots between the white lines in Fig.  5a–f, the 
characteristic response seen in infected plasma (Fig. 5a–
e) is not reproduced in the naïve control (Fig. 5f ).
Fluorescent intensity values were corrected for back-
ground intensity (i.e. non-specific binding by second-
ary antibody), and then also for inter- and intra-array 
variation (Additional file 10). Normalized intensity val-
ues were then compared to corresponding responses 
from the naïve control using the LIMMA package 
[47] to determine the significance of each response. 
The number of significantly immunogenic peptides 
found among 12 PvMSP-7 paralogs was 238, but these 
belonged disproportionately to specific paralogs and 
specific plasma age groups. Figure  5h arranges these 
putative B-cell epitopes in order of decreasing spot 
intensity. Four PvMSP-7 paralogs [PvMSP-7A (21%), 
7B (18%), 7K (12%) and 7L (20%)] contained a large 
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Fig. 5 Mapping of putative B-cell epitopes across 12 PvMSP-7 paralogs by peptide microarray. Plasma from naturally infected vivax malaria patients 
was applied to a custom peptide microarray to determine linear B-cell epitopes. The microarray consisted of 2346 spots, representing 1173 peptides 
(each 13 amino acids) derived from the predicted protein sequences of 12 PvMSP-7 paralogs, overlapping by one amino acid and spotted in 
duplicate. a–e Fluorescent response following incubation of the peptide microarray with patient plasma, pooled by age in years: 0–14 (a), 15–29 
(b), 30–44 (c), 45–59 (d), 60–74 (e), and application of a Cy3 (red) conjugated, secondary goat anti-human IgG antibody. Each spot on the peptide 
microarray corresponds to one peptide. f Negative control consisting of plasma derived from naïve patients living in malaria-free areas. Control 
peptides (HA) are located around the edge of the array and are stained with Cy3 (red) conjugated anti-HA antibody. For comparison, the strongest 
responding spots are highlighted between the white lines. g A Venn diagram showing the overlap in predicted linear B-cell epitopes across 
five patient age groups. 13 peptides that gave significant responses in all experimental groups were observed to be present in all age groups. h 
Peptides that gave fluorescent responses significantly greater than the naïve control in one or more age groups (N = 236) are presented in order of 
response intensity and shaded by PvMSP-7 paralog. The predicted amino acid sequence of the epitope is given for 13 peptides that were significant 
in all five age groups
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proportion of predicted epitopes; six other PvMSP-7 
proteins (PvMSP-7C, 7E, 7F, 7G, 7H, and 7J) each con-
tributed less than 5% of putative epitopes, while no sig-
nificant responses were detected against PvMSP-7D.
Figure  5g shows the number of putative epitopes 
by plasma age group as a Venn diagram. Age group 
of 30–44 displayed the highest number of the sig-
nificant intensity values (n = 123), followed by 0–14 
(n = 121), 15–29 (n = 110), 60–74 (n = 83), and 45–59 
(n = 71). The responses for the 45–59 age cohort are 
weak by comparison with others, and not, on appear-
ance, substantially different to the naïve cohort. The 
lack of response from the 45–59 age cohort cannot be 
explained by sampling artefact, given that it consisted 
of 10 individuals sampled at different times. Neverthe-
less, although plasma from the 45–59 age cohort are 
not generally more responsive than the naïve plasma, 
all of the ‘universal’ epitopes identified below were spe-
cifically recognized by these infected plasma, and to a 
degree significantly greater than naive plasma.
Of the 236 spots that responded significantly to 
infected plasma, 13 putative epitopes were detected 
in all age groups (Table  3). These universal epitopes 
were found in five PvMSP-7 proteins (PvMSP-7A, 7B, 
7H, 7I, and 7L), but 6/13 were derived from PvMSP-
7A. These universal epitopes are not always among the 
most immuno-reactive (Fig. 5h), but 6/13 occur among 
the 10% most responsive peptides and three of these 
are derived from MSP-7A. The position of these puta-
tive epitopes in relation to predicted protein secondary 
structure is shown in Fig. 6.
Discussion
Ten patients infected with vivax malaria were recruited 
from two areas of Thailand and examined the expression 
of, and immune response to, MSP-7 paralogs. Analysis 
of gene expression in asynchronous P. vivax infrapopula-
tions is uncommon, but a recent study by Kim et al. [50] 
generated transcriptomes for three Cambodian clinical 
isolates; their parasite gene expression profiles had strong 
positive correlations  (r2 > 0.8), regardless of the differ-
ences in the proportions of developmental stages in the 
original infections. The current analysis presents another 
picture; isolates display diverse parasite expression pro-
files that appear to reflect differences in the developmen-
tal composition of parasite infrapopulations. Variation 
in expression profile between PvMSP-7 paralogs in the 
clinical isolates has been identified that correlates with 
broader differences in developmental stage-specific gene 
expression, as well as with substantial variation in the 
natural immune response to PvMSP-7 proteins; together, 
these findings indicate that gene paralogy is an important 
factor in MSP-7 vaccine design.
MSP-7 is characterized by its developmental regula-
tion during the merozoite stage, its cell-surface locali-
zation, and it is a prominent role in the cell invasion 
machinery [11, 12, 16, 18, 19, 24, 51–53]. So the positive 
co-expression of PvMSP-7C, 7H and 7I with a schizont 
stage-specific marker (i.e. SEA1), as well as a cluster of 
other invasion-related genes, in patients that had expe-
rienced longer patency is consistent with the current 
understanding. These MSP-7 genes are part of an inva-
sion-related gene cohort, transcription of which is known 
to be specifically upregulated during schizogony through 
Table 3 Sequence, parent gene and  structural position of  13 PvMSP-7 peptides that  gave significant responses 
on the peptide microarray in all age groups, compared to the negative control
a Mean value across all age groups
Epitope sequence PvMSP7 paralog Position within protein 
sequence (aa)
Signal intensity paadj
Infecteda Naive
CLLLLCAGPVLGDDD A 10–25 10.0182341 6.403 0.003
EAVQWGPATEEVVAE A 158–173 10.9368279 7.083 0.002
KLLDTMLTNGQVERE A 298–313 9.47392489 6.693 0.009
TMLTNGQVEREKKNT A 302–317 9.09588506 5.900 0.014
EREKKNTLIKTFKKA A 310–325 8.31646604 4.383 0.004
KNTLIKTFKKALYDK A 314–329 5.52137066 0.000 0.012
YESIHGEDEPQVVPS B 178–193 8.86022031 5.274 0.009
EEESLGHLLESEDAD H 83–98 9.86610447 6.932 0.011
DEIHVPPFHSKYNDF I 272–287 9.52211097 7.151 0.016
EDTTPKEQQEDQNVS L 91–106 8.74109552 5.510 0.012
QEENTQVKNVIFTEK L 123–138 9.29166832 4.963 0.010
EAVDEEAEKEDTAVI L 139–154 11.8856457 7.626 0.002
SSAESAPNEPDVNTT L 207–222 10.2973557 8.476 0.026
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the activation of RNA polymerase II, in contrast to the 
majority of blood-stage genes, which are constitutively 
expressed throughout the IDC [54]. Based on the abun-
dance of specific markers for schizont, liver and game-
tocyte stages, it is clear that the composition of parasite 
infrapopulations in the ten patients varied, and that these 
differences caused the result seen in Fig.  1. Contrasting 
with these conventional observations, the high abun-
dance of PvMSP-7A and 7F in all patients and, by exten-
sion, their lack of correlation with stage-specific markers, 
indicates that these two paralogs are expression through-
out the IDC. Thus, the authors contend that PvMSP-7A 
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Fig. 6 Observed linear B-cell epitopes mapped to predicted secondary protein structures of 12 PvMSP-7 proteins. The cartoon depicts the 
intensity and position of linear B-cell epitopes identified by microarray within each PvMSP-7 protein. The x-axis shows the secondary structure 
of each paralog to scale, as predicted by JPred4 [65]: coiled-coil (grey line), alpha-helix (red lozenge), beta-strand (blue arrows). The intrinsically 
unstructured/disordered regions (blue zig-zag line) was predicted using the GeneSilico MetaDisorder service [66]. The positions of 236 peptides 
giving significant responses from the microarray are plotted; the y-axis measures the epitope coverage of a given amino acid position (maximum of 
four epitopes). The positions of 13 ‘universal’ epitopes observed in all assays (see Fig. 5g) are marked by black bars and their corresponding epitope 
sequences
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and 7F have undetermined roles during ring and tropho-
zoite stages in addition to the familiar function on the 
merozoite surface. PvMSP-7A and 7F show significantly 
less structural variation in natural populations than other 
family members and higher rates of purifying selection, 
which offers circumstantial evidence for their being func-
tionally differentiated [12, 21]. It can only speculated as 
to what these additional functions might be. PvMSP-7 
was seen to be a ligand for the host receptor P-selectin 
[55]. This study did not determine which paralog, if not 
all, was implicated in this interaction, but this makes 
the general point that binding specificities for host pro-
teins may vary widely within the gene family, and those 
of PvMSP-7A and 7F may relate to intracellular proteins 
encountered by asexual blood stages, in addition to host 
cell surface proteins bound by invading merozoites.
If this view that variation in expression reflects func-
tional diversity is correct, then the same consistent 
patterns should be evident in transcriptomes from syn-
chronous cell cultures. Figure  7 describes the MSP-7 
expression profiles in synchronous cell cultures of P. 
vivax [25], P. falciparum [56], and P. berghei [57]. None 
of these studies explicitly examined MSP-7; note that 
the species differ in the number of paralogs. The P. vivax 
transcriptome was described by Bozdech et al. [25] who 
used microarrays to capture transcriptional changes dur-
ing the IDC over 48  h, from the early ring to schizont 
stage. 11/13 PvMSP-7 genes increased expression from 
early schizont stage to late schizont stage. Consistent 
with the present data, PvMSP-7A and 7F were expressed 
most strongly throughout the IDC, while MSP-7G and 7J 
were the rarest forms (Fig. 7a; [25]). López-Barragán et al. 
[56] used RNA-seq to measure gene expression in syn-
chronized P. falciparum cultures, from ring- to ookinete 
stage. Their data present a similar pattern to the situation 
in P. vivax; two paralogs, PfMSP-7A and 7I were highly 
abundant in all stages, while PfMSP-7G and 7H only 
become abundant in the schizont (Fig. 7b; [56]). Finally, 
a P. berghei transcriptome based on RNA-seq from syn-
chronized ring to ookinete stages [57] also shows that one 
paralog (PbMSP-7C) maintains high abundance through-
out, while other paralogs (PbMSP-7A and 7B) peaked 
in expression during the schizont stage (Fig.  7c; [57]). 
Clearly, in all species, MSP-7 expression peaks generally 
during the late trophozoite-schizont transition, when 
merozoites are forming. However, in all species, there is 
a minority of paralogs that maintain abundant expression 
throughout the IDC, further supporting the view that the 
MSP-7 family may have additional functions besides their 
established role on the surface of the invading merozoite.
The presence of these constitutively expressed para-
logs (within the context of the IDC) in multiple species 
raises the possibility that they are orthologous, and thus, 
suggestive of functional differentiation that is conserved 
across the genus. There are two PvMSP-7 genes with 
unambiguous orthologs in the other species: 7A and 
7K [13]. PvMSP-7A (orthologous to MSP-7H in P. falci-
parum and MSP-7A in P. berghei) did not show similar 
expression patterns across the IDC. While PvMSP-7A 
expression began in the early ring stage and peaked at 
early schizont stage [25], PfMSP-7H was transcribed on 
from late trophozoite to gametocyte II, and absent after 
gametocyte stage V [56]. PbMSP-7A likewise did not 
maintain its expression throughout the IDC, but was 
strongly associated with the schizont stage [57]. Mean-
while, PvMSP-7K (orthologous to MSP-7C in P. berghei) 
is expressed exclusively during early to late schizont 
stage [25] while, PbMSP-7C was constitutively expressed 
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Fig. 7 Comparison of MSP-7 expression profiles from published 
transcriptomes of synchronized cell cultures in multiple Plasmodium 
species. a Expression profiles for 12 PvMSP-7 genes in P. vivax, as 
determined by microarray analysis [25]. b Expression profiles for 
seven PfMSP-7 genes in P. falciparum across seven blood-stages, as 
determined by cDNA sequencing [56]. c Expression profiles for four 
PbMSP-7 genes in P. berghei, across five life stages, as determined by 
RNA-seq [57]. All values are log2-transformed. Shading represents 
transcript abundance from low (red) to high (black). An asterisk and 
hash indicate two sets of orthologous genes in different species 
respectively
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throughout the IDC [57]. It is clear from the MSP-7 gene 
phylogeny [13] that the constitutively expressed paral-
ogs in each species do not cluster together as orthologs, 
and are, in fact, drawn from different lineages within the 
family. The combination of longer-expressed and briefly-
expressed genes is conserved but the genes performing 
these contrasting roles are not. This suggests that the 
functional need for different roles is constant but is ful-
filled in different species by a rapidly changing MSP-7 
repertoire.
PvMSP-7A has been identified, from among the several 
paralogs, as eliciting the strongest and most consistent 
immune responses in natural vivax malaria infections. 
This may be because PvMSP-A is more exposed to the 
immune system, being more abundant than other para-
logs that are expressed by a smaller proportion of the 
parasite infrapopulation. Peptide arrays have been used 
successfully elsewhere to map linear B-cell epitopes of 
various vaccine candidates, including other merozoite 
surface proteins such as MSP1 and MSP3 [58]. Jaenisch 
et al. [59] used peptide microarrays assayed with serum 
from malaria patients to test a range of P. falciparum pro-
teins preselected for their in silico antigenicity. Among 
the significant epitopes they discovered were several spe-
cific to PfMSP7. Peptide arrays have also been used to 
examine variant antigens, which are certainly important 
mediators of the immune response, but more challenging 
to study than low-copy number proteins, and to identify 
epitopes of RIFIN and STEVOR proteins that are asso-
ciated with severe falciparum malaria in Malian children 
[60].
These studies have their limitations; the peptide arrays 
are printed using bacterial cell systems that may not 
accurately recreate eukaryotic protein decorations cru-
cial to recognition in nature. They also do not address 
conformational or discontinuous epitopes. Nonetheless, 
antibody responses to malaria antigens on these arrays 
correlate well with measurements of purified proteins 
using enzyme-linked immunosorbent assays (ELISAs) 
[58]. In the present study, only epitopes that were sig-
nificant in all age cohorts were selected, yet responses 
from the 45–59 age cohort were clearly lower than other 
groups, perhaps limiting the number of universal, signifi-
cant epitopes that could be detected.
Clearly, the natural immune responses to PvMSP-7 
would be expected to lead to some level of protection 
against infection. However, associations with protection 
are inconsistent, probably reflecting the complexity of 
each local situation and their resident parasite popula-
tions. Crompton et al. [58] found that high antibody titres 
to several vaccine candidate antigens (LSA-3, MSP-1, and 
MSP-2) had no statistically significant association with 
protection from uncomplicated malaria in Malian chil-
dren. In contrast, the same markers were predictive of 
protection in Kenyan children [61]. Finding a somewhat 
intermediate position, Nixon et  al. [30] examined the 
relationship between epitope-specific PfSEA-1 antibody 
levels and protection from P. falciparum in a longitudinal 
treatment-reinfection cohort in Kenya. They observed 
that antibodies to three epitopes were associated with 
16 to 17% decreased parasitaemia. The MSP-7 epitopes 
identified here would likely meet a similar situation, iden-
tifying the relevant B-cell epitopes enables further studies 
of the protective properties of PvMSP-A but, in all likeli-
hood, these natural responses will need to be enhanced 
through optimization of adjuvant and delivery protocols 
if they are to protect against malaria.
Conclusion
With these results, the impact that functional variation 
within the PvMSP-7 gene family could have for vac-
cine development can be assessed. MSP-7 proteins are 
promising vaccine candidates due to their cell surface 
position and their prominence in interactions between 
host and invading parasite [14]. In this, they resemble 
the reticulocyte-binding protein (RBP) family, another 
multi-copy gene family developed as vaccine candidates 
in both P. vivax [62] and P. falciparum [63, 64]. Care-
ful consideration has been given to diversity within the 
RBP family and to the optimal selection on gene copies. 
Of the eleven PvRBP genes, two paralogs, PvRBP1a and 
PvRBP1b, are both favoured as vaccine candidates as 
they localize to the microneme during schizogony and 
bind host ligands during reticulocyte invasion [62]. Han 
et  al. favoured these two paralogs as vaccine candidates 
because they displayed a consistent antigenicity that 
elicited a protective immune response in a mice model. 
PvMSP-7 antigens vary widely, but consistently, in their 
expression during blood infections, and in their anti-
genicity with respect to B-cell responses. This study has 
shown that, as with PvRBP, it cannot be assumed that the 
12 MSP-7 paralogs are equal in their antigenic proper-
ties, or equally plausible as vaccine candidates. Previous 
work has shown that MSP-7A is among the most struc-
tural conserved of PvMSP-7 paralogs in natural P. vivax 
populations [20–22]; this work has shown that PvMSP-
7A is also expressed for the longest interval during blood 
infections and is the most immunogenic antigen. Hence, 
of all PvMSP-7 gene copies, PvMSP-7A is the optimal 
selection for vaccine development.
Page 18 of 20Cheng et al. Malar J          (2019) 18:197 
Additional files
Additional file 1. Transcript abundance values (CPM) for RNA-seq data 
mapped to 5838 Plasmodium vivax PvPO1 genes. Log2 transformed nor-
malized read counts for 5838 genes generated by DEseq2 after mapping 
RNA-seq data with Tophat2.
Additional file 2. Principal component analysis (PCA) of ten clinical 
isolates based on transcriptome-wide single nucleotide polymorphisms 
(SNPs). RNA-seq data for each clinical isolate was mapped to the P. vivax 
PvPO1 reference genome (5838 genes) and SNPs (N = 42,988) were 
extracted using the Genome Analysis Toolkit, version 3.7. SNPs were 
filtered using the linkage disequilibrium pruning method and PLINK 
version 1.9. A sliding window size of 50 was set across the transcriptome, 
advancing with steps of five SNPs, and SNPs with a threshold value 
above 0.5 were removed. Isolate identity and Patient Groups are labelled. 
Geographical origin is denoted by coloured symbols: red circle (Yala), blue 
square (Ubon Ratchathani).
Additional file 3. Genes showing significant differential expression in 
pairwise comparisons of Patient Groups. Results of differential expression 
tests in pairwise comparisons of Patient Groups 1–4 using DEseq2. Fold-
change is log2-transformed. p-value is Bonferroni-corrected for multiple 
tests. Differentially expressed genes are defined as having an adjusted p 
value < 0.05 and are shaded red. Significant MSP-7 genes are listed first.
Genes showing significant differential expression in pairwise comparisons 
of Patient Groups. Results of differential expression tests in pairwise com-
parisons of Patient Groups 1–4 using DEseq2. Fold-change is log2-trans-
formed. p-value is Bonferroni-corrected for multiple tests. Differentially 
expressed genes are defined as having an adjusted p value < 0.05 and are 
shaded red. Significant MSP-7 genes are listed first.
Additional file 4. A heatmap describing the profiles of 251 differentially 
expressed genes (y-axis) between Patient Groups 1 and 4 (x-axis). Data 
displayed are log2 transformation of normalized raw reads using DESeq2. 
The heatmap is divided into four sectors. Significant GO terms and/
or KEGG pathways in each sector are shown in tables on the right. GO 
terms and/or KEGG pathways with adjusted p-value<0.05 were deemed 
significant. The colour scale represents the expression level of DEGs: red 
(lower expression), black (higher expression). Patient Groups are labelled 
by colour beneath the dendrogram.
Additional file 5. A heatmap describing the profiles of 351 differentially 
expressed genes (y-axis) between Patient Groups 2 and 4 (x-axis). Data 
displayed are log2 transformation of normalized raw reads using DESeq2. 
The heatmap is divided into four sectors. Significant GO terms and/
or KEGG pathways in each sector are shown in tables on the right. GO 
terms and/or KEGG pathways with adjusted p-value < 0.05 were deemed 
significant. The colour scale represents the expression level of DEGs: red 
(lower expression), black (higher expression). Patient Groups are labelled 
by colour beneath the dendrogram.
Additional file 6. Clusters of co-expressed genes generated from 
transcript abundance data and their enriched GO/KEGG terms. In pairwise 
comparisons of Patient Groups, transcript abundance values for DEGs 
were analysed with coseq, to produce clusters of genes with expression 
profiles displaying significant positive correlations. Comparison of Patient 
Groups 3 and 4, 2 and 4 and 1 and 4 generated 14, 7 and 6 clusters respec-
tively; the membership of these clusters is shown in three separate tabs, 
with notable stage-specific genes and MSP-7 shaded red. Also shown are 
the results of enrichment analyses for selected clusters in each compari-
son (i.e. those displaying a distinct profile with respect to patient group 
4), and a filtered table of the same results showing only non-redundant 
ontological terms.
Additional file 7. Clusters of genes co-expressed between Patient Groups 
1 and 4. Normalized read counts from the DESeq2 analysis were used to 
generate clusters of genes with positively correlated transcription profiles 
using coseq. 251 DEGs formed six clusters; four clusters with dynamics 
that clearly distinguish the two patient groups are shown here. Boxplots 
(left) represent individual patient, shaded by Patient Group; the black 
line connecting boxplots is the mean expression value of all genes in the 
cluster. a) MSP-7C is co-expressed with 20 other genes such as PIESP1, 
PMV, and rhoptry neck protein 3 (RON3, PvP01_1469200). b) MSP-7H is co-
expressed with 12 other genes including serine-repeat antigen-1 (SERA, 
PvP01_0417100), subtilisin-like protease 3 (SUB3, PvP01_1026800), and 
high molecular weight rhoptry protein 3 (RhopH3, PvP01_0703800). c) A 
gametocyte-specific marker, gamete release protein (PvP01_0115300), 
was co-expressed with TRAG28 and PHISTc, but negatively correlated with 
PvMSP-7H and other invasion related genes. d) Another gametocyte-spe-
cific marker, gamete antigen 27/25, was co-expressed with Plasmodium 
exported protein (PHIST, PvP01_0734900) and tryptophan-rich protein 18 
(TRAG18, PvP01_1033900). The line graphs (right) show the expression 
pattern of each gene in the cluster across all patients, and specific genes 
are labelled. Pearson’s correlation coefficient (r) for abundance values of 
MSP-7H and these selected genes are shown.
Additional file 8. Clusters of genes co-expressed between Patient Groups 
2 and 4. Normalized read counts from the DESeq2 analysis were used to 
generate clusters of genes with positively correlated transcription profiles 
using coseq. 351 DEGs formed seven clusters; four clusters with dynamics 
that clearly distinguish the two patient groups are shown here. Boxplots 
(left) represent individual patient, shaded by Patient Group; the black 
line connecting boxplots is the mean expression value of all genes in the 
cluster. a) Two PvMSP-7H and -7I are co-expressed with 26 other genes 
including ETRAMP, rhoptry neck protein 12 (RON12, PvP01_0602300), 
and membrane associated erythrocyte binding-like protein (MAEBL, 
PvP01_0948400). b) The schizont stage-specific marker SEA1 is co-
expressed with 77 other genes such as parasite-infected erythrocyte sur-
face protein (PIESP1, PvP01_0829800) and MOP. c) A gametocyte-specific 
marker, gamete antigen 27/25, clustered with 31 other genes including 
Plasmodium exported protein (PHIST, PvP01_0001440) and tryptophan-
rich protein (TRAG24, PvP01_1470100). d) Another stage-specific marker, 
liver stage antigen 3, clustered with 69 other genes such as Plasmodium 
exported protein (PHIST, PvP01_0119200) and tryptophan-rich protein 
(TRAG28, PvP01_0000130), but was negatively correlated with PvMSP-7H.
Additional file 9. A spreadsheet describing the layout of all 1173 pep-
tides contained on the custom peptide microarray. Peptide map of 13 
MSP7 protein sequences elongated with neutral GSGSGSG linkers at the 
C- and N-terminus and translated into overlapping peptides, with peptide 
length of 15 amino acids and peptide overlap of 11 amino acids. Green 
and red peptides denote positive controls.
Additional file 10. Fluorescent signal intensity for 236 peptide spots on 
a custom PvMSP-7 peptide microarray that gave significant responses to 
human plasma from natural infections. Signal intensity values in infected 
and naïve plasma are shown for 236 putative B-cell epitopes identi-
fied using a custom MSP-7 peptide microarray, assayed with plasma 
from clinical vivax malaria infections. Plasma were pooled into five age 
groups. Peptides shown gave significant responses when normalized 
using LIMMA (p-value adjusted form multiple tests), i.e. the response was 
significantly greater than the corresponding response from naïve, unin-
fected patients. For each peptide, the relevant PvMSP-7 paralog is named, 
and the number of age groups for which the peptide gave a significant 
response is specified.
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